(Press-News.org) Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer’s disease (AD), but its role in the brain was unknown until now. In a paper published in Nature, researchers from Mass General Brigham used preclinical models to uncover Tim-3’s role in microglia, the brain's resident immune cells, and have identified it as a promising therapeutic target for Alzheimer’s disease.
“Immune checkpoint inhibitors have revolutionized cancer immunotherapy, and it is exciting that we might be able to repurpose them to treat Alzheimer’s disease,” said senior author Vijay Kuchroo, PhD, DVM, of the Gene Lay Institute of Immunology and Inflammation at Brigham and Women’s Hospital and Massachusetts General Hospital, founding members of the Mass General Brigham healthcare system. “Microglia are pivotal in neuroinflammation and neurodegeneration, and therapeutic targeting of Tim-3 in microglia may alter them to an optimal state to fight the disease pathology in AD. “
Using a mouse model of AD, the Kuchroo lab together with Oleg Butovsky lab, at the Ann Romney Center for Neurologic Diseases at BWH, determined that Tim-3 is only expressed in microglia in the central nervous system, where it helps the cells maintain a healthy state of homeostasis. Tim-3 can also, however, prevent the brain from effectively clearing out the toxic plaques that accumulate during AD. The researchers found that deleting Tim-3 helped kickstart plaque removal by prompting the microglia to eat up more of the plaques, while also producing anti-inflammatory proteins to reduce neuroinflammation, and limiting cognitive impairment.
Over a half-dozen clinical trials are currently testing therapeutics that target Tim-3 to treat patients with immunotherapy-resistant cancers. According to the authors, the new study highlights the therapeutic potential of adapting these treatments to enhance plaque clearance and mitigate neurodegeneration in Alzheimer’s disease.
Authorship: In addition to Kuchroo, Mass General Brigham authors include Kimitoshi Kimura, Ayshwarya Subramanian, Zhuoran Yin, Ahad Khalilnezhad, Yufan Wu, Danyang He, Karen Dixon, Udbhav Kasyap Chitta, Xiaokai Ding, Niraj Adhikari, Isabell Guzchenko, Xiaoming Zhang, Ruihan Tang, Thomas Pertel, Aastha Aastha, Masashi Nomura, Lei Liu, Conner Lambden, Kilian L. Kleemann, Neha Gupta, Jen-Li Barry, Ana Durao, Yiran Cheng, Sebastian Silveira, Huiyuan Zhang, Aamir Suhail, Dennis J. Selkoe, Howard L. Weiner, Mario L. Suvà, and Oleg Butovsky. Other authors include Samuel A. Myers, Ghazaleh Eskandari-Sedighi, Vasundhara Singh, Toni Delorey, Orit Rosenblatt-Rosen, Gordon J. Freeman, Mathew Blurton-Jones, Carlos Cruchaga, and Aviv Regev.
Disclosures: Blurton-Jones is a co-founder and consultant for Savanna Biotherapeutics (formally NovoGlia Inc). Selkoe is a founding director of Prothena Biosciences and an ad hoc consultant to Eisai. Suvà is an equity holder, scientific co-founder, and advisory board member of Immunity Therapeutics. Butovsky has a collaboration with GSK and Regulus Therapeutics, receiving research funding from Sanofi and GSK, and honoraria for lectures and consultancy from UCB, Camp4, and Ono Pharma USA. He is also a co-founder of and has an ownership interest in Glial Therapeutics and General Biophysics. Kuchroo has an ownership interest in and is a member of the scientific advisory board for Larkspur Biosciences. He is also a co-founder of and has an ownership interest in Tizona Therapeutics and Bicara Therapeutics.
Funding: This work was supported by the NIH-NIAID (P01 AI073748, R01 AI144166, P01 AI056299, P01 AI056299), NIH-NIA (R01 AG080992, R01AG054672, R01AG051812, R01AG075509, R21AG076982, R01 AG082704, U19AG069701), and Cure Alzheimer’s Fund (2021, 2022, ApoE Consortium, Neuroimmune Consortium), NIH-NINDS (R01NS088137), NIH-NEI (R01EY027921), BrightFocus Foundation (2020A016806). The UCI-ADRC iPSC core is funded by NIH AG066519.
Paper Cited: Kimura, K, et al. “Tim-3 immune checkpoint regulates microglial function and Alzheimer's disease” Nature DOI[AM1] : 10.1038/s41586-025-08852-z
END
Potential Alzheimer’s disease therapeutic target identified in brain immune cells
2025-04-09
ELSE PRESS RELEASES FROM THIS DATE:
New gene editing tool shows promise for treating diseases with multiple mutations
2025-04-09
Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without causing unwanted mutations. The system can be formulated completely as RNA, dramatically simplifying delivery logistics compared to traditional systems that use both RNA and DNA. By inserting an entire gene, the tool offers a one-and-done approach that overcomes hurdles from CRISPR gene editing technology—which is programmed to correct individual mutations—offering a promising step forward for gene therapy. Results are published in Nature.
“CRISPR ...
Longest known seafaring venture 8,500 years ago brings hunter-gatherers to Malta before early farmers
2025-04-09
Seafaring hunter-gatherers were accessing remote, small islands such as Malta thousands of years before the arrival of the first farmers, a new international study has found.
Published in Nature, the research team – led by Professor Eleanor Scerri of the Max Planck Institute of Geoanthropology (MPI-GEA) and the University of Malta – found hunter-gatherers were crossing at least 100km of open water to reach the Mediterranean island of Malta 8,500 years ago, a thousand years before the arrival of agricultural practises.
This ...
How human cells repair damaged DNA
2025-04-09
The DNA of human cells consists of a sequence of about 3.1 billion building blocks. Cells go to great lengths to maintain the integrity of this vast store of information. They constantly untangle knots in the DNA strand and create new chemical bonds when a strand of DNA breaks somewhere in the nucleus.
“When people read about repairing genetic material, they often think of it being in response to exposure to toxins or radiation,” says Jacob Corn, Professor of Genome Biology at ETH Zurich. However, repair mechanisms not only defend against external threats; they also play a crucial role in helping cells survive the challenges they ...
Your skin is breathing. New wearable device can measure it.
2025-04-09
Northwestern University researchers have developed the first wearable device for measuring gases emitted from and absorbed by the skin.
By analyzing these gases, the device offers an entirely new way to assess skin health, including monitoring wounds, detecting skin infections, tracking hydration levels, quantifying exposure to harmful environmental chemicals and more.
The new technology comprises a collection of sensors that precisely measure changes in temperature, water vapor, carbon dioxide (CO2) and volatile organic compounds (VOCs), which each give valuable ...
Serendipitous discovery could lead to more efficient catalysts
2025-04-09
PULLMAN, Wash. – Preparing catalysts by sending hot, steamy car exhaust over them could improve their efficiency and reduce the amount of rare and expensive metals required in vehicle catalytic converters and many other emission control and industrial processes.
Reporting in the journal, Nature, an international team of researchers found that the hot car exhaust containing nitrogen oxides and carbon monoxide caused a previously unknown reaction that, used proactively, can significantly improve catalytic activity. Catalysts are substances that increase the rate of chemical reactions.
The researchers found that hot exhaust encouraged ceria particles, one of the components of the ...
Engineering smart delivery for gene editors
2025-04-09
Overcoming Delivery Challenges in Gene Editing
Modern genome editing techniques, including CRISPR systems, hold great potential for treating genetic diseases. However, delivering these molecular tools reliably to their target cells remains a significant challenge.
“Previous viral and non-viral delivery systems such as adeno-associated viruses (AAVs), lipid nanoparticles (LNPs), and other virus-like particles (VLPs), have been valuable but face limitations,” says Dr. Dong-Jiunn Jeffery Truong, last author ...
Six ape genomes sequenced telomere-to-telomere
2025-04-09
Comprehensive reference genomes have now been assembled for six ape species: siamang (a Southeast Asian gibbon), Sumatran orangutan, Bornean orangutan, gorilla, bonobo and chimpanzee. Areas of their genomes previously inaccessible because of structural complexity have now mostly been resolved.
The resource is already lending itself to comparative studies that offer new insights into human and ape evolution, and into what underlies the functional differences among these species.
A report on how the telomere-to-telomere ape genome references were developed, and what scientists are learning from it, appears in the April 9 edition ...
Hubble Space telescope unveils the first images of ongoing star cluster mergers near the center of dwarf galaxies
2025-04-09
A new study reports the first direct observation of merging star clusters in the nuclear region of dwarf galaxies. This detection confirms the feasibility of this formation route for nuclei in dwarf galaxies, which has long been debated. The study was published in Nature science journal, and led by Postdoctoral Researcher Mélina Poulain from the University of Oulu, Finland.
Dwarf galaxies are the most abundant type of galaxies that populate the Universe. Composed of 100 times fewer stars than the ...
‘Sugar’ signatures help identify and classify pancreatic cancer cell subtypes
2025-04-09
GRAND RAPIDS, Mich. (April 9, 2025) — Van Andel Institute scientists and collaborators have developed a new method for identifying and classifying pancreatic cancer cell subtypes based on sugars found on the outside of cancer cells.
These sugars, called glycans, help cells recognize and communicate with each other. They also act as a cellular “signature,” with each subtype of pancreatic cancer cell possessing a different composition of glycans.
The new method, multiplexed glycan immunofluorescence, combines ...
Every cloud has a silver lining: DeepSeek’s light through acute respiratory distress syndrome shadows
2025-04-09
Acute respiratory distress syndrome (ARDS) continues to be a tough nut to crack in critical care, taking lives despite years of research and better ventilator strategies. It is defined by acute hypoxemia, bilateral infiltrates on chest imaging, and non-cardiogenic pulmonary edema, and it remains a heterogeneous condition with mortality rates stubbornly close to 40%. Its complexity—spanning diverse etiologies, inflammatory profiles, and therapeutic responses—demands innovative solutions beyond traditional paradigms. In recent years, artificial intelligence ...